Evotec SE today announced that it has completed the repayment of the € 140 m debt bridge facility Evotec drew down in context of the acquisition of Aptuit in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-repayment-of-eur-140-m-acquisition-loan-5801